Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

FDA Official Describes How QbD is Shifting Reviewers' Thinking

This article was originally published in The Gold Sheet

  • News
  • The Gold Sheet

Executive Summary

"I went through several BLAs (biologics license applications) and these were randomly selected. … What is obvious is that in a typical BLA we do have a fairly wide range of parameters that are listed with ranges that are specified and these ranges are supported by data from clinical work, but more importantly from the validation runs that are done to support these parameters."

Table

View full table

Tags:
Latest Headlines

Brand Drug Shortages Complicate US FDA Messaging To Congress

Relyvrio’s Failure Sparks NeuroSense ALS Development Changes

Pink Sheet Podcast: BIOSECURE Act Advances, Trial Diversity Sticks, Platform Principles Without Designation

FTC Is Taking A Tougher Stance On Pharma, A Deputy Director Explains Why

See All
UsernamePublicRestriction

Register

PS000544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By